Graig Suvannavejh
Stock Analyst
(3.19)
# 3,630
Out of 4,648 analysts
134
Total ratings
48.04%
Success rate
0.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $39 → $38 | $28.56 | +33.05% | 6 | Oct 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $42 → $52 | $33.05 | +57.34% | 15 | Oct 10, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterates: Outperform | $74 | $18.31 | +304.15% | 1 | Sep 20, 2024 | |
| ATHA Athira Pharma | Downgrades: Neutral | $5 → $0.5 | $0.64 | -21.86% | 3 | Sep 19, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $44 → $49 | $58.47 | -16.20% | 6 | Jul 22, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Outperform | $50 | $30.00 | +66.67% | 1 | Jul 8, 2024 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | $20 | $11.71 | +70.79% | 1 | Jul 8, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $96 → $100 | $86.17 | +16.05% | 9 | Jun 21, 2024 | |
| AXSM Axsome Therapeutics | Reiterates: Buy | $106 | $87.25 | +21.49% | 16 | Jun 12, 2024 | |
| INSM Insmed | Maintains: Buy | $36 → $82 | $68.09 | +20.43% | 6 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $0.83 | +262.54% | 1 | May 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $9.35 | +71.12% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $5.70 | -47.37% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $88 | $31.17 | +182.32% | 6 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $30 | $11.70 | +156.41% | 4 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $22 | $7.54 | +191.78% | 4 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $8 | $1.86 | +330.11% | 1 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 | $9.02 | -61.20% | 1 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $7.10 | +40.85% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $5.27 | +70.78% | 4 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $0.64 | +520.25% | 8 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $3.87 | +287.60% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $52.99 | -33.95% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $3.90 | +105.13% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $51.48 | +10.72% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $24.36 | -79.47% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $5.85 | +481.20% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $5.32 | +426.32% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $34.48 | -10.09% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $19 | $0.78 | +2,335.90% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.83 | +159.56% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $8.72 | +312.84% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $26.71 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $1.20 | +2,983.33% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $109.41 | +16.99% | 1 | Sep 14, 2020 |
Apellis Pharmaceuticals
Oct 24, 2024
Maintains: Neutral
Price Target: $39 → $38
Current: $28.56
Upside: +33.05%
Harmony Biosciences Holdings
Oct 10, 2024
Maintains: Outperform
Price Target: $42 → $52
Current: $33.05
Upside: +57.34%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $18.31
Upside: +304.15%
Athira Pharma
Sep 19, 2024
Downgrades: Neutral
Price Target: $5 → $0.5
Current: $0.64
Upside: -21.86%
Halozyme Therapeutics
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $58.47
Upside: -16.20%
IDEAYA Biosciences
Jul 8, 2024
Initiates: Outperform
Price Target: $50
Current: $30.00
Upside: +66.67%
Neumora Therapeutics
Jul 8, 2024
Initiates: Outperform
Price Target: $20
Current: $11.71
Upside: +70.79%
Intra-Cellular Therapies
Jun 21, 2024
Maintains: Buy
Price Target: $96 → $100
Current: $86.17
Upside: +16.05%
Axsome Therapeutics
Jun 12, 2024
Reiterates: Buy
Price Target: $106
Current: $87.25
Upside: +21.49%
Insmed
Jun 7, 2024
Maintains: Buy
Price Target: $36 → $82
Current: $68.09
Upside: +20.43%
May 17, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $0.83
Upside: +262.54%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $9.35
Upside: +71.12%
May 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $5.70
Upside: -47.37%
May 13, 2024
Maintains: Buy
Price Target: $90 → $88
Current: $31.17
Upside: +182.32%
May 7, 2024
Maintains: Buy
Price Target: $39 → $30
Current: $11.70
Upside: +156.41%
Apr 29, 2024
Maintains: Buy
Price Target: $40 → $22
Current: $7.54
Upside: +191.78%
Apr 2, 2024
Maintains: Buy
Price Target: $20 → $8
Current: $1.86
Upside: +330.11%
Mar 27, 2024
Maintains: Neutral
Price Target: $3.5
Current: $9.02
Upside: -61.20%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $7.10
Upside: +40.85%
Nov 17, 2023
Maintains: Buy
Price Target: $10 → $9
Current: $5.27
Upside: +70.78%
Aug 23, 2023
Reiterates: Neutral
Price Target: $4
Current: $0.64
Upside: +520.25%
Mar 31, 2023
Initiates: Buy
Price Target: $15
Current: $3.87
Upside: +287.60%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $52.99
Upside: -33.95%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $3.90
Upside: +105.13%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $51.48
Upside: +10.72%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $24.36
Upside: -79.47%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $5.85
Upside: +481.20%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $5.32
Upside: +426.32%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $34.48
Upside: -10.09%
Mar 2, 2021
Initiates: Sell
Price Target: $19
Current: $0.78
Upside: +2,335.90%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.83
Upside: +159.56%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $8.72
Upside: +312.84%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $26.71
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $1.20
Upside: +2,983.33%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $109.41
Upside: +16.99%